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The ages of puberty, first sexual intercourse and first birth signify the onset of reproductive 
ability, behaviour and success, respectively. These sequenced events have behavioural, 
physiological and health significance, and may also influence overall reproductive fitness. In 
a genome-wide association study of 125,667 white men and women aged 40-69 in the UK 
Biobank Study, we identify 38 sequence variants with association P-values <5×10-8 with age 
at first sexual intercourse. Findings were taken forward in up to 241,910 men and women 
from deCODE Iceland and 20,187 from Women’s Genome Health Study. Several of these loci 
also exhibit strong associations with behavioural traits (rs4856591 in CADM2 and risk taking 
propensity: P=4.3×10-10; rs73195303 in MSRA and irritable temperament: P=5.8×10-11) and 
other reproductive traits (rs67229052 in ESR1 and both age at first birth: P=1.2x10-13 and 
number of children: P=4.8×10-12; rs2188151 in SEMA3F and age at first birth: P=8.76×10-15). 
In Mendelian randomisation analyses, we demonstrate likely causal influences of earlier 
puberty timing on earlier first sexual intercourse, earlier first birth and fewer years of 
education. In turn, likely causal consequences of earlier first sexual intercourse include 
reproductive, educational, psychiatric and cardiometabolic outcomes. These findings point 







The age of puberty, the transition from childhood to sexual maturity and reproductive 
ability, has fallen markedly over the last century in most populations, illustrated by the 
average age at menarche of 18 years in 1880 to 12.5 years in 1980 (ref.1,2). This decline was 
initially observed in industrialized, western countries, and more recently, and often far more 
rapidly, in countries with more recent economic transitions3. These changes likely reflect 
increases in childhood nutrition and body size, but exposures to endocrine disrupting 
chemicals or other specific environmental factors have also been proposed1. In 
contemporary cohorts, earlier puberty timing, in both men and women, is associated with 
greater propensity towards risk-taking behaviours4,5, lower educational attainment, greater 
susceptibility to several adverse health outcomes6 and, in women, to increased mortality.7 
Conversely, it has been proposed that earlier puberty timing is a life-history strategy that 
promotes greater reproductive fitness8. Yet, despite some reports that earlier puberty 
timing is associated with younger age at first sexual intercourse (AFS)9,10 and younger age at 
first birth (AFB), there is yet little evidence that this trait is associated with reproductive 
fitness11. 
In contrast to the small body of evidence on the role of puberty timing on AFS, most 
research on the predictors or determinants of AFS is contextualized in terms of the social, 
economic and cultural environment, including the nature of interpersonal relationships. 
Hence, established correlates of younger AFS include social disadvantage, family instability, 
low levels of parental monitoring, and lack of religious affiliation and belief12-14. In particular, 
parental and peer norms and behaviours have a strong influence on teenagers’ sexual 
behaviour14-16. Twin studies have suggested some genetic contribution to AFS17,18, however 
observations of older AFS among monozygous compared to dizygous twins13 casts doubt on 
the validity of twins studies to accurately estimate the heritability of this trait. 
Recent genome-wide association studies (GWAS) have identified 123 sequence variants 
independently associated with timing of menarche in females19, and these signals appear to 
have concordant effects on puberty timing also in males20. A valuable application of such 
GWAS findings is the use of genetic variants, with robust association with a specified trait, as 
instrumental variables in (“Mendelian randomisation”) analyses to test the likely causal 
relationships with that trait with less risk of confounding compared to traditionally observed 
associations21. Here, we use this approach to test the causal relationship of puberty timing19 
to AFS and AFB. We also perform a GWAS to identify sequence variants associated with AFS 
and AFB, and use these findings to test the causal relationships between the timings of the 





Shared genetic architecture between reproductive onset traits 
We used whole-genome LD score regression22 to test the genetic correlations between the 
timings of puberty, first sexual intercourse and first birth; such correlations quantify the 
extent of shared genetic architecture. Data on genome-wide SNP associations with puberty 
timing were recently reported19. To generate such scores for the other two traits, we 
performed association tests across a genome-wide panel of ~46M SNPs for self-reported 
AFS and AFB (recorded in women only) in 59,357 men and 66,310 women in the UK Biobank 
study. In this sample, median and inter-quartile range (IQR) for AFS was 18 years (16-21) in 
men and 18 years (17-21) in women, median (IQR) AFB was 25 years (22-28) (recorded in 
women only), and the SNP-based test REML23 indicated moderate heritability for AFS both in 
men (h=0.248, s.e. 0.010) and in women (h=0.242, s.e. 0.010), and also moderate heritability 
for AFB (h=0.290, s.e. 0.015, women only). Using the three scores, we found moderately 
strong positive genetic correlations between puberty timing and AFS, both in women 
(rg=0.22, P=1.2×10
-16) and men (rg=0.26, P=9.5×10
-8), and between puberty timing and AFB 
(rg=0.24, P=9.0×10
-13; women only). Furthermore, we found a remarkably strong genetic 
correlation between AFS and AFB (rg=0.86, P=3.1×10
-136).  
Genetic correlations have been reported between puberty timing and a range of other 
health-related traits, including inverse correlations with body mass index (BMI), type 2 
diabetes (T2D) and cardiovascular disease (CVD)20. In the same way, we used whole-genome 
LD score regression22 to test genetic correlations between AFS and other health-related 
traits using publicly available GWAS datasets or original GWAS findings in UK Biobank (see 
Methods). We identified genetic correlations between AFS and 22 of the 44 tested 
outcomes or traits after correction for multiple testing (P<1.1×10-3), including inverse 
correlations with BMI, T2D and CVD, and also with a variety of behavioural (e.g. smoking; 
alcohol intake) and neurological traits (e.g. intelligence; risk taking propensity) and 
psychiatric outcomes (attention deficit hyperactivity disorder (ADHD); schizophrenia) 
(Figure 2). 
In a sex-combined GWAS in UK Biobank, we identified 33 loci with variants associated at 
P<5×10-8 with AFS (Table 1, Figure 1, Figure S1-2). Nine of these loci showed sex-discordant 
associations (Pheterogeneity<0.05), and subsequent sex-specific models identified an additional 
five signals, four in men and one in women (Table 1). Across these 38 AFS loci, effect sizes 
ranged from 0.02-0.33 SDs, minor allele frequencies (MAF) ranged from 0.15% to 49%. 
Seventeen of these variants were associated with AFS at the more stringent P-value 
threshold P<1×10-9. In UK Biobank, no loci were found associated at P<5×10-8 with AFB in 
women. 
In the absence of other large GWAS for AFS, we relied on the strong genetic correlation 
between AFS and AFB in women to collectively confirm our genetic findings in two 
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independent datasets: deCODE (N=117,626 males, 124,284 females) and the Women’s 
Genome Health Study (WGHS, N=20,187 women). A weighted SNP genotype score of our 38 
novel signals for AFS was strongly associated with AFB in both deCODE (P=3.3×10-21) and 
WGHS (P=9.2×10-4) (Table S1, S2 and S6).  The subset of 21 ‘less stringently associated’ AFS 
variants (those with association P-values: 1×10-9≥P<5×10-8) was also collectively associated 
with AFB (weighted SNP genotype score in deCODE: P=3.1×10-7). 
Biological determinants of age at first sexual intercourse 
None of the 38 lead AFS-associated variants (or their r2>0.8 proxies) were non-synonymous 
SNPs, however several were located in regions containing promoter/enhancer histone 
marks, DNAse hypersensitive sites or protein binding sites (Table S3). In addition, the 
majority of these variants either altered regulatory motifs or were associated in cis with 
gene expression (Table S4) 
To identify mechanisms that might regulate AFS, we performed a systematic test of all 
annotated biological pathways for enrichment of genes located near to AFS-associated 
signals, using MAGENTA (see Methods, Table S5). Four pathways were associated with AFS: 
“Circadian clock system”, “Packaging of telomere ends”, RNA Polymerase-I promoter 
opening and “NOTCH HLH transcription”.  
We then tested puberty timing and body size as specific a priori candidate determinants of 
AFS, by performing Mendelian randomization analyses in the UK Biobank sample. For each 
exposure, we created a genetic instrumental variable by calculating a weighted allele score 
from the SNP genotypes at reported signals with robust associations with each phenotype 
(see methods, Tables S6-S10). In both men and women, genetically-predicted earlier 
puberty timing (Pwomen=2.0×10
-9, Pmen=4.7×10
-11) and genetically-predicted greater BMI 
(Pmen=5.5×10
-8, Pwomen=2.2×10
-4) appeared to promote earlier AFS (Tables S7-S8). 
Genetically-predicted greater height appeared to promote later AFS in men (P=1.0×10-5) and 
in women (P=1.1×10-3) (Table S9), which is consistent with reported non-genetic 
associations between greater height and later AFB in European men and women24.  
Prompted by our observation of a novel AFS locus near MC1R (rs369230 r2=0.12 with the 
variant rs12931267 that is strongly associated with hair colour)25,26, we tested genetic 
instrumental variables for skin freckling and hair colour, which are traits regulated by this 
gene25,26. Genetically-predicted skin freckling appeared to promote later AFS in women 
(P=6.3×10-9) but not in men (P=0.47), and genetically-predicted red hair appeared to 
promote later AFS in both men (P=0.02) and women (P=9.3×10-5; Table S10). 
Relationships to other behavioural, reproductive and health outcomes 
To test whether puberty timing and AFS might be causally related to other behavioural, 
reproductive and health outcomes, we performed Mendelian randomization analyses using 
weighted allele scores calculated from SNP genotypes at signals associated with puberty 
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timing19 or AFS (described above) as genetic instrumental variables for these traits. To 
reduce bias, we avoided testing health outcomes in the same datasets that were used to 
generate the allele weightings (i.e. outcomes related to AFS were tested in datasets other 
than UK Biobank). Genetic associations were scaled to indicate the likely causal effect of a 
one SD change in normalised puberty timing or AFS.   
Genetically-predicted earlier puberty timing decreased the age at leaving education 
(standardised beta: 0.061, P=4.0×10-7; in UK Biobank) (Table S11). Similarly, genetically-
predicted earlier AFS decreased the likelihood of attaining university-level education 
(standardised OR=0.74, P=3.7×10-5; in publicly-available Social Science Genetic Association 
Consortium data) and increased the likelihood of ever-smoking (standardised OR=1.33, 
P=2.0×10-3; in publicly-available Tobacco and Genetics Consortium data) (Table S9). For 
reproductive outcomes, in the deCODE data, each one SD genetically-predicted earlier AFS 
promoted earlier AFB (women: standardised beta=1.71, P=2.2×10-17; men: 1.69, P=2.6×10-13; 
combined P=3.3×10-21), a greater number of children (women: standardised beta= 0.035, 
P=0.006; men: 0.012, P=0.34; combined P=0.0044), and lower likelihood of being childless 
(women: standardised OR=0.67, P=0.034; men: OR=0.66, P=0.009; combined P=0.0022) 
(Table S1). Similarly, each one SD genetically-predicted earlier puberty timing promoted 
earlier AFB (standardised beta: 0.37, P=5.8×10-8; assessed in UK Biobank women only) and 
earlier age at last birth (0.37, P=3.7×10-7; in UK Biobank women), but had little effect on 
other reproductive outcomes (Tables S6 and S11). 
We noted that several of the 38 novel AFS signals were located in or near genes reportedly 
implicated in brain development (BARHL2, SEMA3F, ZIC4/ZIC1, DPYSL4, DIAPH3), or 
neuronal activity and/or susceptibility to schizophrenia/bipolar disorder (CADM2, LRP4, 
GRIA4, CACMA1D, HCN1, GRIA4, DRD2, FURIN, GNAL and VRK2) (Table 1 and S3), consistent 
with our observed shared genetic architecture between AFS and ADHD (rg= -0.38, P=5.9×10
-
4), and between AFS and schizophrenia (rg= -0.10, P=7.3×10
-4) (Figure 2). We used a bi-
directional Mendelian randomisation approach to test the likely causal relationships: 
susceptibility to schizophrenia appeared to lower AFS (in UK Biobank with or without 
exclusion of individuals with self-reported psychiatric illness: P=0.005; Table S13), but also, 
earlier AFS appeared to increase susceptibility to schizophrenia (in publicly available 
Psychiatry Genetics Consortium data, P=4.1×10-11, Table S12), suggesting a pleiotropic 
relationship between these traits. The substantial shared genetic architecture between AFS 
and self-reported risk taking propensity (rg= -0.46, P=7.3×10
-28) (Figure 2) gives insights into 
possible common determinants of AFS and schizophrenia.  
To explore potential specific neuro-behavioural mechanisms that might contribute to the 
aetiology of AFS, we performed a look-up of the 38 individual AFS loci for associations with 
fifteen other behavioural, reproductive and health-related traits in UK Biobank and other 




CADM2 and MSRA loci influence multiple behavioural traits 
The AFS signal represented by rs57401290 is intronic in CADM2, which encodes a neuronal 
cell-adhesion molecule. rs57401290, or highly correlated SNPs in this locus, also showed 
genome-wide significant associations in UK Biobank with: self-reported risk taking 
propensity (rs57401290: P=5.3×10-9; r2=0.65 with the lead CADM2 SNP for this trait 
rs4856591: P=4.3×10-10), number of sexual partners (rs57401290: P=6.0×10-7; r2=0.60 with 
lead SNP rs5850688: P=4.1×10-8) and number of children (rs57401290: P=6.2×10-7, r2=0.65 
with lead SNP rs4856591: P=3.8x10-11, replication in deCODE P=0.006) (Table S14). In each 
case, the AFS-decreasing allele conferred higher values of those outcomes. rs57401290 is 
modestly correlated with the reported signal at this locus for BMI27 (r2=0.11 with 
rs13078960, the AFS-decreasing allele also increases BMI) and is strongly correlated with 
the reported signal in CADM2 for cognitive processing speed28 (rs17518584 r2=0.80, the 
AFS-decreasing allele also decreases processing speed). CADM2 shows highest expression in 
the prefrontal cortex and is involved in a range of neuronal processes, including glutamate 
signaling, gamma-aminobutyric acid transport and neuron cell-cell adhesion28. 
The AFS-decreasing allele at rs658385 (~25 kb downstream of MSRA) was also associated in 
UK Biobank with lower likelihood of self-reported irritable temperament (P=3.8×10-4) and 
was modestly correlated (r2=0.14) with the lead MSRA SNP for this trait (rs73195303, 
P=5.8×10-11). Conditional analyses excluded the presence of independent secondary signals 
for AFS or irritable temperament at this locus. The enzyme encoded by MSRA reduces 
methionine sulfoxide to methionine and hence repairs proteins that have been inactivated 
by oxidative stress, which is a candidate mechanism in cognitive impairment and 
schizophrenia/bipolar disorder29. Overexpression of msra in the fruit fly Drosophila is 
reported to markedly delay reproductive capacity and extend life span30. 
ESR1 and RBM6/SEMA3F loci influence reproductive traits 
The AFS-decreasing allele at rs726281 (intronic in ESR1, which encodes the estrogen 
receptor) was also associated in UK Biobank with earlier AFB in women (P=6.9×10-3), higher 
number of children in women (P=7.0 ×10-5) (Figure 3). This locus contains a moderately 
correlated intronic variant rs67229052 in ESR1 (r2=0.25) that is also associated with AFS 
(P=1.6×10-10), AFB (P=2.4×10-7), and number of children in women (P=3.7×10-8) in UK 
Biobank (Table 2). In deCODE and WGHS these associations with rs67229052 were robustly 
confirmed in women and, in deCODE, were extended to include men (rs67229052: AFB in 
men P=6.7×10-9; number of children in men P=1.9×10-6; Table 2). Conditional analyses 
excluded the presence of independent secondary signals at this ESR1 locus for either AFS or 
AFB and, apart from modest correlation between rs726281 and the reported adult height 
variant (r2=0.16 with rs3020418), rs726281 and rs67229052 were unrelated to the reported 
GWAS signals in this gene for puberty timing, breast cancer, breast size and bone mineral 
density (all r2<0.05). 
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The AFS signal at rs2188151 is highly correlated with a missense variant in SEMA3F (r2=0.7 
with rs1046956; Leu503Met in semaphorin-3F isoform X2), which encodes a semaphorin 
protein, and is a cis eQTL for RBM6 (P=5×10-143), which encodes an RNA binding protein. 
rs2188151 is correlated with the reported GWAS signals for HDL (r2=0.45 with rs2013208) 
and puberty timing (r2=0.18 with rs2188151); in publicly available ReproGen consortium 
data the AFS-decreasing allele confers later puberty timing. In both men and women (Table 
2), the AFS-decreasing allele at rs2188151 was also associated with earlier AFB (sex 
combined: P=8.76×10-15), greater BMI (P=3.6×10-15; look-up in publicly available GIANT 
consortium data: P=3.9×10-5), a greater number of children (P=9.05×10-5) and lower 
likelihood of being childless (P=9.38×10-5).  
DISCUSSION 
Here, we show that a substantial proportion of the variation in AFS is due to genetic factors, 
which likely act through a variety of biological mechanisms, many of which influence either 
physical traits, such as puberty timing, or personality characteristics, such as risk-taking 
propensity. Previous studies have invariably focused on only the socio-cultural determinants 
of AFS and the relevance of early AFS to poor educational achievement and other adverse 
outcomes12,13. We recognise the importance of diverse socio-cultural factors, which are 
reflected by the discordant changes in AFS and AFB seen by year of birth in the UK Biobank 
study (Figure S4). However, despite such marked secular changes, the genetic contribution 
to AFS has remained stable over time (estimated heritability in men and women born pre-
1950: h=0.262, s.e. 0.017; in those born in 1950 onwards: h=0.283, s.e. 0.015). 
The neuro-behavioural traits associated with AFS can be broadly categorised as stimulus-
seeking (risk taking) and moderating traits such as intelligence and neuroticism (irritability). 
Risk taking is itself related to an exuberant temperament and is moderated by executive 
function31, which are neurocognitive traits implicated in both AFS17,18 and schizophrenia32-34. 
Furthermore, our extended findings with the AFS signal at CADM2 indicate that neuro-
behavioural traits, such as cognitive processing speed28 and risk taking propensity, may also 
have important relevance to measures of reproductive success, such as number of children. 
We suggest that future population-based study designs to study the pre-morbid personality 
and cognitive traits associated with schizophrenia and bipolar disorder may inform the 
psychological and biological processes that contribute to reproductive behaviour and 
fecundity. 
A notable finding was the AFS locus intronic in ESR1. Effects of estrogen signalling on 
reproductive ability in women have been long predicted from models of response to 
fertility-inducing hormones35,36, consistent with effects of estrogens on promoting ovarian 
follicle maturation and uterine receptivity to implantation37,38. Estrogen receptors are highly 
expressed in male pituitary, prostate, testis, breast and liver (Figure S3), and disrupted 
signalling leads to low sperm concentrations and infertility, both in humans39,40 and in a 
rodent model41. However, the variants at this locus that we found associated with 
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reproductive behaviour (AFS) and reproductive success (AFB) in both sexes, were largely 
unrelated to the ESR1 variants reportedly associated with other traits (puberty timing, 
breast cancer, breast size and bone mineral density). The possibility of a central tissue-
specific effect of this ESR1 variant rs67229052 is supported by its demonstration as an eQTL 
for ESR1 in only one of ~50 GTEX tissues (with “brain_caudate_basal_ganglia”, using the 
r2=0.98 proxy rs4305732); the allele associated with higher ESR1 expression (P=0.0004) is 
also associated with later AFS, later AFB and fewer children. Central estrogen receptor 
signalling was recently described as a biological regulator of socio-reproductive behaviours 
in male mice42. Our findings support a neuro-behavioural role for ESR1 in both men and 
women. Furthermore, our findings of robust associations between AFS-associated ESR1 
variants and number of children and likelihood of being childless in mid-late adult life 
suggest that central processes, such as hypothalamic-pituitary sex hormone signalling and 
neuro-cognitive traits, may contribute to reproductive success. 
Our genetic findings indicate that both physical maturation and neuro-behavioural traits 
contribute to the timing of reproductive activity and success, with consequences for 
educational and behavioural outcomes. Consideration of individual variation in pubertal 
timing and also personality characteristics, such as high risk-taking propensity and low 
neuroticism, may contribute to targeted and more effective approaches to health education 





The UK Biobank study design has been reported43. Briefly, all people aged 40–69 years who 
were registered with the National Health Service and living up to ~25 miles from one of the 
22 study assessment centres were invited to participate in 2006-10. Overall, about 9.2 
million invitations were mailed in order to recruit 503,325 participants (i.e. a response rate 
of 5.47%)44. Extensive self-reported baseline data were collected by questionnaire, in 
addition to anthropometric assessments. Details of the phenotypes analysed here are 
shown in Table S15. All participants provided informed written consent, the study was 
approved by the National Research Ethics Service Committee North West – Haydock, and all 
study procedures were performed in accordance with the World Medical Association 
Declaration of Helsinki ethical principles for medical research. 
Genetic analysis in UK Biobank 
We analysed data from the May 2015 release of imputed genetic data from UK Biobank, 
containing ~73M SNPs, short indels and large structural variants in 152,249 individuals. Full 
details are published (see URLs). Briefly, the samples were genotyped on two slightly 
different arrays. Approximately 50,000 were genotyped by a custom UL BiLEVE study array, 
and the remaining samples (~100,000) were genotyped on the UK Biobank Axiom array from 
Affymetrix, which was specifically designed to optimize imputation performance in GWAS 
studies. Removal of SNPs with missing data, multi-allelic SNPs, SNPs with a minor allele 
frequency (MAF) <1%, and 1,037 sample outliers, resulted in a dataset with 641,018 
autosomal SNPs in 152,256 samples for phasing and imputation. Imputation was performed 
using a reference panel created by merging the UK10K haplotype panel with the 1000 
Genomes Phase 3 reference panel.  
In addition to the quality control metrics performed centrally by UK Biobank, we defined a 
subset of “white European” ancestry samples using a K-means clustering approach applied 
to the first four principle components calculated from genome-wide SNP genotypes. All 
individuals defined in this group also self-identified by questionnaire as being of white 
ancestry. Autosomal SNPs were analysed by linear mixed models implemented in BOLT-
LMM23 to account for cryptic population structure and relatedness within this group in our 
genetic association tests. X chromosome SNPs were analysed using SNPTEST45. Genotyping 
chip was included as a binary covariate in all models. Any SNPs with an imputation quality < 
0.4 or MAF < 0.1% were excluded post-analysis. After application of QC criteria, a maximum 
of 142,630 individuals were available for analysis with genotype and phenotype data. There 
was no substantial effect on test statistics after exclusion from the models of those 
individuals with any reported psychiatric illness. Genomic loci were defined on the basis of 
physical proximity using a 1 Mb window. Signals were excluded from consideration if they 
were significantly associated with genotyping chip. 
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Variance component analyses were performed in the subset of individuals of only “white 
british” genetic ancestry (maximum analysed N=99,241) using Restricted Estimate Maximum 
Likelihood (REML) models in BOLT-LMM46. Genetic variance was calculated on all QC’d 
genotyped autosomal SNPs, adjusting for chip status and the top 5 genetically determined 
principal components. 
Replication studies 
deCODE Genetics: Whole genomes of 8,453 Icelanders were sequenced using Illumina 
technology to a mean depth of at least 10X (median 32X) and SNPs and indels identified and 
their genotypes called using joint calling with the Genome Analysis Toolkit HaplotypeCaller 
(GATK version 3.3.0)47. Genotype calls were improved by using information about haplotype 
sharing, taking advantage of the fact that all the sequenced individuals had also been chip-
typed and long range phased. Around 30M sequenced variants were then imputed into 
150,656 Icelanders who had been genotyped using the Illumina HumanHap300, 
HumanCNV370, HumanHap610, HumanHap1M, HumanHap660, Omni-1, Omni 2.5 or Omni 
Express bead chips48. SNPs were excluded if they had (i) yield <95%, (ii) MAF <1% in the 
population or (iii) significant deviation from Hardy–Weinberg equilibrium (HWE) (P<0.001), 
(iv) if they produced an excessive inheritance error rate (over 0.001) or (v) if there was 
substantial difference in allele frequency between chip types (from just a single chip if that 
resolved all differences, but from all chips otherwise). All samples with a call rate below 97% 
were excluded from the analysis. Using genealogic information, the sequence variants were 
imputed into 294,212 un-typed relatives of chip-typed individuals to further increase the 
sample size for association analysis and increased the power to detect associations. The 
study was approved by the Data Protection Commission of Iceland and the National 
Bioethics Committee of Iceland.  All subjects gave their written informed consent. 
Women's Genome Health Study (WGHS): WGHS derives from the 23,294 Women’s Health 
Study (WHS) European ancestry participants who provided baseline blood samples. They 
represent approximately 72% of the 39,876 initially healthy female healthcare professionals, 
aged >45 years at baseline, who participated in a randomized, placebo controlled trial of 
aspirin and vitamin E in primary prevention over 10 years of incident CVD. The Institutional 
Review Board of Brigham and Women’s Hospital, Boston, approved all analyses49. 
Genotyping was performed using the HumanHap300 Duo ‘‘+’’ platform (Illumina, San Diego, 
CA) with the Infinium II protocol. For quality control, all samples were required to have 
successful genotyping using the BeadStudio v.3.3 software (Illumina, San Diego, CA) for at 
least 98% of the SNPs.  The subset of 23,294 women had self-reported European ancestry 
that could be verified by multidimensional scaling analysis of identity-by-state using 1,443 
ancestry informative markers in PLINK v.1.06.  In the final dataset, a total of 339,596 SNPs 
were retained with: MAF >1%, call rate >90%, and HWE P<10-6. Genotypes for a total of 
30,052,423 (autosomes) + 1,264,493 (X) SNPs were imputed from the experimental 
genotypes and phase information from the 1000G phase I v.3 release (March 2012) ALL 
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panel using MaCH (v. 1.0.16) and Minimac (release 5/29/2012). 332,927 genotyped SNPs 
that were selected by HWE P>10-6 but unrestricted by MAF could be reconciled with the 
1000G ALL panel and were used for imputation. 
 
Genetic correlations  
Genetic correlations (rg) were calculated between puberty timing, AFS, AFB and 44 other 
complex traits/diseases in publicly-available datasets using LD Score Regression22 (see 
URLs). Genome-wide SNP association were also generated in UK Biobank for the following 
traits: number of children, childlessness, number of sexual partners, smoking status, alcohol 
intake, years of education, risk taking propensity, suffering from nerves, irritability, 
happiness, and intelligence. Details of these phenotypes are described in Table S15. A 
conservative Bonferroni corrected P-value threshold of P<1.1×10-3 [=0.05/44] was used to 
define significant associations. 
Mendelian Randomization  
Mendelian randomization is an analytical method to infer the likely causal unconfounded 
causal relationship between an exposure trait and an outcome. It is considered to be more 
accurate than estimate causal , using genetic variants that are associated with the exposure 
trait and do not influence the outcome by other unrelated biological pathways 
(‘pleiotropy’)21. We calculated using weighted allele scores from SNP genotypes at signals 
robustly associated with each modelled exposure as genetic instrumental variables for those 
traits. SNP genotypes were based on reported GWAS for adult height50, BMI27, puberty 
timing19, schizophrenia51, skin freckling and hair colour25, or from the current GWAS for AFS 
in UK Biobank. To avoid bias, outcomes were tested in datasets (UK Biobank, deCODE, 
WGHS or publicly-available datasets) that were independent of the discovery GWAS for 
each exposure. The associations with weighted allele scores were scaled to indicate the 
causal effect of a one SD change in the normalised exposure variable (Table S6). 
Pathway analyses and functional insight of SNPs 
Meta-Analysis Gene-set Enrichment of variaNT Associations (MAGENTA - 
https://www.broadinstitute.org/mpg/magenta/) was used to test the full genome-wide 
discovery dataset for genetic associations with the biological pathways defined by Gene 
ontology, PANTHER, KEGG and Ingenuity. MAGENTA implements a gene set enrichment 
analysis (GSEA) based approach, where each gene in the genome is mapped to a single 
index SNP with the lowest P-value within a 110 kb upstream, 40 kb downstream window. 
This P-value, representing a gene score, is then corrected in a regression model for 
confounding factors such as gene size, SNP density and LD-related properties. Genes within 
the HLA-region were excluded from analysis due to difficulties in accounting for gene 
density and LD patterns. Each mapped gene in the genome is then ranked by its adjusted 
13 
 
gene score. At a given significance threshold (95th and 75th percentiles of all gene scores), 
the observed number of gene scores in a given pathway, with a ranked score above the 
specified threshold percentile, is calculated. This observed statistic is then compared to 
1,000,000 randomly permuted pathways of identical size. This generates an empirical GSEA 
P-value for each pathway. Significance was determined when an individual pathway reached 
a false discovery rate (FDR) <0.05 in either analysis. In total, 3216 pathways were tested for 
enrichment of multiple modest associations with AFS. 
Each AFS-associated locus was annotated for possible genomic functions using ENCODE and 
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Figure 1 | Manhattan plot of the GWAS for age at first sexual intercourse  
Manhattan plot illustrating results of the genome-wide association study (GWAS) meta-
analysis for age at first sexual intercourse in up 59,357 men and 66,310 women of European 
descent in the UK Biobank study. -log10 P-values for each SNP (Y-axis) are plotted by 
chromosomal position (X-axis). The red line indicates the threshold for genome-wide 
statistical significance (P=5×10-8). Blue dots represent SNPs within a 1Mb base pair window 





Figure 2 | Bar chart of genetic correlations age at first sexual intercourse 
Whole-genome LD score regression tested genome-wide SNP associations for age at first 
sexual intercourse against similar data for 44 other traits. Blue (positive correlation) and red 
(negative correlation) bars indicate the 22 traits that showed a significant genetic 
correlation after correction for multiple testing (P<1.1×10-3). †Women only. ‡Men only. 
Abbreviations: ADHD – attention deficit hyperactivity disorder; Repro. – reproductive traits; 






Figure 3 | Cluster plot displaying associations between the 38 ‘age at first sexual 
intercourse’ lead SNPs and 15 other behavioural, reproductive and health-related traits in 
UK Biobank.  
*Indicates the nine traits that are significantly enriched for age at first sexual intercourse 
(AFS) signals. All SNPs are aligned to the AFS-increasing allele. Both SNPs and phenotypes 
are clustered by patterns of association. To facilitate clustering, some phenotypes have 
been inverted and these have the label “(Inv.)” (e.g. number of children, BMI, risk-taking 
propensity). Blue shading indicates a positive association with the indicated variable; red 
shading indicates a negative association. Hierarchical clustering of both phenotypes and 
SNPs was based on the Ward method using Euclidian distances. Abbreviations: BMI - body 





Table 1 | The 38 genome-wide significant loci for Age at First Sexual Intercourse (AFS) in UK Biobank 
Variant Location Nearest gene Alleles2 Effect (s.e) P-value Sex Het 
rs115552537 1p22.2 BARHL2 A/C/0.22 0.03 (0.005) 1.30E-08 6.66E-01 
rs10800813 1q32.1 GPR37L1 C/T/0.63 0.02 (0.004) 3.80E-08 5.56E-01 
rs4324362 2p21 CAMKMT G/A/0.38 0.03 (0.004) 1.30E-11 1.14E-01 
rs1344293 2p16.1 BCL11A G/T/0.48 0.03 (0.004) 3.30E-15 1.87E-01 
rs1040124 2q12.1 TMEM182 A/G/0.57 0.02 (0.004) 2.50E-08 1.96E-01 
rs1264194 3p21.31 COL7A1 C/T/0.71 0.03 (0.004) 5.10E-09 1.57E-01 
rs2188151 3p21.31 SEMA3F G/T/0.57 0.03 (0.004) 3.00E-11 7.85E-01 
rs34337122 3p21.1 CACNA1D CG/C/0.85 0.03 (0.005) 8.80E-09 7.62E-01 
rs6549665 3p12.3 CNTN3 G/C/0.18 0.03 (0.005) 4.90E-08 9.20E-01 
rs12714592 3p12.1 CADM2 A/C/0.73 0.03 (0.004) 1.80E-10 4.34E-01 
rs57401290 3p12.1 CADM2 GGTGTGT/G/0.55 0.03 (0.004) 8.00E-14 1.32E-03 
rs530580221 3q24 ZIC4 T/TA/0.38 0.03 (0.004) 2.00E-09 9.22E-01 
rs12522910 5p12 HCN1 C/T/0.17 0.04 (0.005) 2.70E-12 2.47E-01 
rs726281 6q25.1 ESR1 A/G/0.72 0.03 (0.004) 3.20E-11 6.58E-01 
rs13239969 7p22.3 MAD1L1[e] C/G/0.6 0.02 (0.004) 1.40E-08 6.39E-01 
rs4840367 8p23.1 MFHAS1 A/G/0.41 0.02 (0.004) 1.70E-10 4.35E-01 
rs658385 8p23.1 MSRA T/C/0.55 0.02 (0.004) 6.70E-09 2.92E-02 
rs2248699 8p23.1 BLK[e] G/A/0.5 0.02 (0.004) 3.60E-10 3.28E-01 
rs538498277 9q21.12 SMC5 C/G/0.998 0.31 (0.051) 6.90E-10 4.86E-02 
rs4443996 10q26.3 LRRC27 A/C/0.52 0.02 (0.004) 1.30E-08 8.40E-01 
rs535814333 11p11.2 ATG13 TTG/T/0.7 0.02 (0.004) 3.90E-09 1.39E-02 
rs140976226 11q22.3 GRIA4 GTT/G/0.43 0.02 (0.004) 1.00E-09 2.51E-02 
rs66821824 11q23.2 NCAM1 ATTTT/A/0.78 0.03 (0.005) 1.60E-09 3.39E-01 
rs538200730 11q24.2 KIRREL3 T/A/0.29 0.03 (0.004) 3.20E-10 8.22E-01 
rs341521 13q21.2 DIAPH3 G/A/0.3 0.03 (0.004) 6.30E-15 4.62E-02 
rs9516776 13q32.1 HS6ST3 A/T/0.34 0.02 (0.004) 3.30E-08 4.87E-01 
rs4702 15q26.1 FURIN[e] A/G/0.56 0.02 (0.004) 2.90E-10 2.79E-02 
rs76513770 16q22.2 PMFBP1 C/T/0.13 0.04 (0.006) 4.70E-09 4.17E-01 
rs369230 16q24.3 CPNE7 G/T/0.31 0.02 (0.004) 7.30E-10 1.02E-04 
rs58749137 18p11.21 GNAL A/G/0.73 0.02 (0.004) 1.30E-08 1.07E-01 
rs4129322 18q21.2 DCC A/G/0.08 0.04 (0.007) 2.90E-10 9.35E-01 
rs6058613 20q11.21 KIF3B C/G/0.16 0.03 (0.005) 3.50E-08 1.67E-02 
rs5932884 Xq26.2 IGSF1 G/A/0.47 0.02 (0.005) 8.41E-09 - 
Women only 
rs961522 2p16.1 VRK2 C/T/0.61 0.03 (0.005) 2.80E-08 4.63E-05 
Men Only 
rs13194984 6p22.2 BTN1A1 G/T/0.86 0.05 (0.009) 3.90E-09 5.21E-05 
rs201909661 11q14.1 DLG2 A/AG/0.02 0.15 (0.02) 7.00E-10 6.09E-07 
rs138057093 18p11.22 RAB31 C/T/0.01 0.20 (0.03) 7.50E-10 7.25E-06 
rs111837587 22q11.1 XKR3 A/G/0.01 0.18 (0.03) 7.20E-09 8.77E-05 
 
1. [e] refers to a gene linked via altered expression (eQTL);2 effect allele / other allele / effect allele frequency
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Table 2 |Association statistics at the ESR1 and RBM6-SEMA3F loci for reproductive outcomes 
  
UK Biobank  
(up to 59,357 men and 66,310 women) 
deCODE (up to 117,626 men, 124,284 
women) and WGHS (up to 20,187 women) Combined 






Age at menarche 0.01 (0.009) 1.20E-01 73,397 - - - 0.01 (0.009) 1.20E-01 73,397 
AFS - Males -0.02 (0.006) 3.70E-04 59,357 - - - -0.02 (0.006) 3.70E-04 59,357 
AFS - Females -0.03 (0.005) 1.40E-08 66,310 - - - -0.03 (0.005) 1.40E-08 66,310 
AFS - Combined -0.03 (0.004) 1.60E-10 125,667 - - - -0.03 (0.004) 1.60E-10 125,667 
AFB - Males - - - -0.19 (0.03) 6.73E-09 117,626 -0.19 (0.03) 6.73E-09 117,626 
AFB - Females -0.15 (0.029) 2.40E-07 50,954 -0.08 (0.02) 6.93E-04 144,471 -0.11 (0.02) 3.58E-09 195,425 
AFB - Combined -0.15 (0.029) 2.40E-07 50,954 -0.12 (0.02) 6.96E-08 262,097 -0.13 (0.02) 1.22E-13 313,051 
Num Child - Males 0.01 (0.003) 8.20E-02 66,498 0.009 (0.002) 1.94E-06 117,626 0.008 (0.002) 7.25E-07 184,124 
Num Child - Females 0.01 (0.003) 3.70E-08 75,540 0.005 (0.002) 1.27E-02 147,498 0.008 (0.002) 2.15E-07 223,038 
Num Child - Combined 0.01 (0.002) 3.20E-07 142,038 0.007 (0.001) 1.11E-06 265,124 0.008 (0.001) 4.82E-12 407,162 
Childless - Males 0.98 (0.01) 1.30E-01 66,498 0.97 (0.02) 2.12E-01 97,200 0.98 (0.01) 5.56E-02 163,698 
Childless - Females 0.95 (0.01) 2.50E-06 75,540 0.93 (0.02) 4.00E-04 117,972 0.94 (0.01) 4.94E-09 193,512 





Age at menarche 0.03 (0.008) 2.20E-05 73,397 - - - 0.03 (0.008) 2.20E-05 73,397 
AFS - Males -0.03 (0.006) 1.60E-05 59,357 - - - -0.03 (0.006) 1.60E-05 59,357 
AFS - Females -0.02 (0.005) 3.60E-07 66,310 - - - -0.02 (0.005) 3.60E-07 66,310 
AFS - Combined -0.03 (0.004) 3.00E-11 125,667 - - - -0.03 (0.004) 3.00E-11 125,667 
AFB - Males - - - -0.14 (0.032) 1.00E-05 117,626 -0.14 (0.032) 1.00E-05 117,626 
AFB - Females -0.16 (0.028) 7.20E-09 50,954 -0.105 (0.024) 7.88E-06 144,471 -0.129 (0.018) 9.52E-13 195,425 
AFB - Combined -0.16 (0.028) 7.20E-09 50,954 -0.115 (0.022) 9.18E-08 262,097 -0.132 (0.017) 8.76E-15 313,051 
Num Child - Males 0.01 (0.003) 2.70E-02 66,498 0.003 (0.002) 7.47E-02 117,626 0.004 (0.002) 7.99E-03 184,124 
Num Child - Females 0.01 (0.003) 1.30E-03 75,540 0.003 (0.002) 7.45E-02 147,498 0.004 (0.001) 1.35E-03 223,038 
Num Child - Combined 0.01 (0.002) 1.60E-04 142,038 0.003 (0.002) 4.06E-02 265,124 0.005 (0.001) 9.05E-05 407,162 
Childless - Males 0.98 (0.01) 3.40E-02 66,498 -0.017 (0.022) 4.27E-01 97,200 -0.023 (0.01) 2.49E-02 163,698 
Childless - Females 0.97 (0.01) 2.50E-03 75,540 -0.028 (0.019) 1.52E-01 117,972 -0.032 (0.01) 8.53E-04 193,512 
Childless - Combined 0.97 (0.008) 2.70E-04 142,038 -0.023 (0.015) 1.42E-01 215,526 -0.028 (0.007) 9.38E-05 357,564 
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